Presentation is loading. Please wait.

Presentation is loading. Please wait.

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

Published byHartanti Oesman Modified over 5 years ago

Similar presentations

Presentation on theme: "Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus."— Presentation transcript:

1 Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial by A. Keith Stewart, David Siegel, Heinz Ludwig, Thierry Facon, Hartmut Goldschmidt, Andrzej J. Jakubowiak, Jesus F. San Miguel, Mihaela Obreja, Julie Blaedel, and Meletios A. Dimopoulos Blood Volume 130(Suppl 1): December 7, 2017 ©2017 by American Society of Hematology

2 A. Keith Stewart et al. Blood 2017;130:743
©2017 by American Society of Hematology

Download ppt "Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus."

Similar presentations

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,
1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.
CARFILZOMIB IFM MARS 2015.

CARFILZOMIB IFM MARS 2015.
1 National and Kapodistrian University of Athens, Athens, Greece; 2 Mayo Clinic, Scottsdale, AZ; 3 Division of Hematology, Mayo Clinic, Rochester, MN;

1 National and Kapodistrian University of Athens, Athens, Greece; 2 Mayo Clinic, Scottsdale, AZ; 3 Division of Hematology, Mayo Clinic, Rochester, MN;
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.

Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.
Andrzej Jakubowiak  Seminars in Hematology 

Andrzej Jakubowiak  Seminars in Hematology 
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
Meletios A. Dimopoulos, MD

Meletios A. Dimopoulos, MD
Alternate designs for conduct and analysis of phase I cancer trials

Alternate designs for conduct and analysis of phase I cancer trials
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Hot Off the Press: Changes in the Landscape of Multiple Myeloma

Hot Off the Press: Changes in the Landscape of Multiple Myeloma
How I treat multiple myeloma in younger patients

How I treat multiple myeloma in younger patients
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,

A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation.

Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation.

Similar presentations

Ads by Google